Resources

In older women with diabetes and urinary incontinence, high A1c levels are associated with patient reports of more severe limitations due to incontinence.…

New data on the inhalable insulin product Technosphere Insulin Afrezza, from MannKind Corp., indicate that the treatment confers no discernible risk for increased cardiovascular (CV) events, while another study examined patient satisfaction with this type of drug.…

Liraglutide, recently approved in the US for the treatment of type 2 diabetes, has demonstrated its potential as a weight-loss drug for nondiabetic, obese patients.…

Zinc may perform a protective function for those with type 2 diabetes, researchers at the University of Michigan suggest….

Users of the smoking-cessation drug varenicline (Chantix) had a small but statistically significant increase in the risk of cardiovascular events, a meta-analysis of randomized trials showed.…

Impaired fasting glucose doesn’t independently increase the risk of cardiovascular events in adults, according to a large new study.…

Patients with depression or diabetes have an increased risk of MI, but the risk is even higher in patients with both conditions, according to a new study.…

Menu labels on college cafeteria food — highlighting the good and the bad of various meal options — make no difference in students’ choices, a new study concludes.…

Discovery makes white fat mimic energy-burning brown fat, muscle.…

This week we examine more of your responses regarding GLP-1 therapy…. See more GLP-1 Agonist Resources. I was glad to see that almost everyone realized that when a GLP-1 agonist is added to a sulfonylurea that it is not the GLP-1 agonist that is responsible for any side effects. It’s …